P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy

Abstract

Definitive chemoradiotherapy (dCRT) is a standard treatment option for patients with unresectable esophageal cancer. Although platinum + fluoropyrimidine-based regimens are comparable in dCRT, overall patient survival is still poor. In patients with advanced, unresectable esophageal cancer, the PD-1 inhibitor pembrolizumab showed promising antitumor activity as monotherapy in the third-line setting in the phase 2 KEYNOTE-180 trial (NCT02559687) and in the second-line setting in the phase 3 KEYNOTE-181 trial (NCT02564263).